Description
রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন।
Indications:
EMJENTA 25/5 MG is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate.
Pharmacology:
Empagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys, increasing urinary glucose excretion. Linagliptin is a DPP-4 inhibitor that increases incretin levels, leading to increased insulin secretion and decreased glucagon release.
Dosage & Administration:
The usual dose is one tablet once daily, taken in the morning with or without food. Dosage should be individualized based on the patient’s medical condition and response to treatment.
Interaction:
Concomitant use with insulin or insulin secretagogues may increase the risk of hypoglycemia. Diuretics may enhance the hypotensive effect of empagliflozin. Other drug interactions should be considered by the physician.
Contraindications:
Contraindicated in patients with known hypersensitivity to empagliflozin, linagliptin, or any of the components of the tablet. Not recommended for type 1 diabetes or for the treatment of diabetic ketoacidosis.
Side Effects:
Common side effects include urinary tract infections, nasopharyngitis, and headache. Hypoglycemia may occur when used with insulin or sulfonylureas. Rarely, pancreatitis or hypersensitivity reactions may occur.
Pregnancy & Lactation:
Not recommended during pregnancy or while breastfeeding due to insufficient data on safety. Use only if clearly needed and prescribed by a physician.
Precautions & Warnings:
Monitor renal function before and during treatment. Use with caution in elderly patients and those with cardiovascular or renal conditions. Avoid dehydration.
Therapeutic Class:
Combination Oral Anti-diabetic preparations (SGLT2 inhibitor + DPP-4 inhibitor)
Storage Conditions:
Store below 30°C, protect from moisture and light. Keep out of reach of children.
Change Language